Advertisement

British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice

Published:November 25, 2021DOI:https://doi.org/10.1016/j.ejogrb.2021.11.423
      The remit of this guideline is to collate and propose evidence-based guidelines for the diagnosis and management of uterine cancer. This document covers all uterine cancers of any histological type.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Concin N.
        • Matias-Guiu X.
        • Vergote I.
        • et al.
        ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
        Int J Gynecol Cancer. 2021; 31: 12-39
        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.
        • Torre L.A.
        • Jemal A.
        Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 68: 394-424
      1. Cancer Research UK. Uterine Cancer Statistics. [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-One.

      2. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and endometrial cancer. . 2018.

        • Moss E.L.
        • Morgan G.
        • Martin A.P.
        • Sarhanis P.
        • Ind T.
        Surgical trends, outcomes and disparities in minimal invasive surgery for patients with endometrial cancer in England: a retrospective cohort study.
        BMJ Open. 2020; 10e036222
        • Njoku K.
        • Barr C.E.
        • Hotchkies L.
        • Quille N.
        • Wan Y.L.
        • Crosbie E.J.
        Impact of socio-economic deprivation on endometrial cancer survival in the North West of England: a prospective database analysis.
        BJOG. 2021; 128: 1215-1224
        • Bokhman J.V.
        Two pathogenetic types of endometrial carcinoma.
        Gynecol Oncol. 1983; 15: 10-17
        • Cancer Genome Atlas Research N
        • Kandoth C
        • Schultz N
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Crosbie E.J.
        • Ryan N.A.J.
        • Arends M.J.
        • et al.
        The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.
        Genet Med. 2019; 21: 2390-2400
        • Hampel H.
        • de la Chapelle A.
        The search for unaffected individuals with Lynch syndrome: do the ends justify the means?.
        Cancer Prev Res (Phila). 2011; 4: 1-5
        • Win A.K.
        • Jenkins M.A.
        • Dowty J.G.
        • et al.
        Prevalence and penetrance of major genes and polygenes for colorectal cancer.
        Cancer Epidemiol Biomarkers Prev. 2017; 26: 404-412
        • Ryan N.A.J.
        • Glaire M.A.
        • Blake D.
        • Cabrera-Dandy M.
        • Evans D.G.
        • Crosbie E.J.
        The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.
        Genet Med. 2019; 21: 2167-2180
        • Ryan N.A.J.
        • McMahon R.
        • Tobi S.
        • et al.
        The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study.
        PLoS Med. 2020; 17e1003263
        • Ryan N.A.
        • Donnelly L.
        • Stocking K.
        • Evans D.G.
        • Crosbie E.J.
        Feasibility of gynaecologist led lynch syndrome testing in women with endometrial cancer.
        J Clin Med. 2020; 9: 1842https://doi.org/10.3390/jcm9061842
        • Snowsill T.M.
        • Ryan N.A.J.
        • Crosbie E.J.
        Cost-effectiveness of the manchester approach to identifying lynch syndrome in women with endometrial cancer.
        J Clin Med. 2020; 9: 1664https://doi.org/10.3390/jcm9061664
      3. National Institute for Health and Care Excellence. NICE Diagnostics Guidance [DG42]. Testing strategies for Lynch syndrome in people with endometrial cancer; 28 October 2020; https://www.nice.org.uk/guidance/dg42/resources/testing-strategies-for-lynch-syndrome-in-people-with-endometrial-cancer-pdf-10538078291892020.

        • Le D.T.
        • Uram J.N.
        • Wang H.
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015; 372: 2509-2520
        • Tashiro H.
        • Blazes M.S.
        • Wu R.
        • et al.
        Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.
        Cancer Res. 1997; 57: 3935-3940
        • Levine R.L.
        • Cargile C.B.
        • Blazes M.S.
        • van Rees B.
        • Kurman R.J.
        • Ellenson L.H.
        PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.
        Cancer Res. 1998; 58: 3254-3258
        • Velasco A.
        • Pallares J.
        • Santacana M.
        • et al.
        Loss of heterozygosity in endometrial carcinoma.
        Int J Gynecol Pathol. 2008; 27: 305-317
        • Mutter G.L.
        • Lin M.C.
        • Fitzgerald J.T.
        • et al.
        Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
        J Natl Cancer Inst. 2000; 92: 924-930
        • Lane DP. Cancer.
        p53, guardian of the genome.
        Nature. 1992; 358: 15-16
        • Goldstein I.
        • Marcel V.
        • Olivier M.
        • Oren M.
        • Rotter V.
        • Hainaut P.
        Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.
        Cancer Gene Ther. 2011; 18: 2-11
        • Ito K.
        • Watanabe K.
        • Nasim S.
        • et al.
        Prognostic significance of p53 overexpression in endometrial cancer.
        Cancer Res. 1994; 54: 4667-4670
        • Geisler J.P.
        • Geisler H.E.
        • Wiemann M.C.
        • Zhou Z.
        • Miller G.A.
        • Crabtree W.
        p53 Expression as a Prognostic Indicator of 5-Year Survival in Endometrial Cancer.
        Gynecol Oncol. 1999; 74: 468-471
        • Moreno-Bueno G.
        • Hardisson D.
        • Sarrio D.
        • et al.
        Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia.
        J Pathol. 2003; 199: 471-478
        • Kurnit K.C.
        • Kim G.N.
        • Fellman B.M.
        • et al.
        CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
        Mod Pathol. 2017; 30: 1032-1041
        • Liu Y.
        • Patel L.
        • Mills G.B.
        • et al.
        Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
        J Natl Cancer Inst. 2014; 106: dju245https://doi.org/10.1093/jnci/dju245
        • Crosbie E.
        • Morrison J.
        The emerging epidemic of endometrial cancer: Time to take action.
        Cochrane Database Syst Rev. 2014; : ED000095https://doi.org/10.1002/14651858.ED000095
        • Gao C.
        • Wang Y.
        • Broaddus R.
        • Sun L.
        • Xue F.
        • Zhang W.
        Exon 3 mutations of CTNNB1 drive tumorigenesis: a review.
        Oncotarget. 2018; 9: 5492-5508
        • Kitson S.J.
        • Bafligil C.
        • Ryan N.A.J.
        • et al.
        BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: a cohort study.
        Eur J Cancer. 2020; 136: 169-175
        • Lee Y.C.
        • Milne R.L.
        • Lheureux S.
        • et al.
        Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
        Eur J Cancer. 2017; 84: 114-120
        • Thompson D
        • Easton DF
        • Breast Cancer Linkage C
        Cancer Incidence in BRCA1 mutation carriers.
        J Natl Cancer Inst. 2002; 94: 1358-1365
        • de Jonge M.M.
        • Auguste A.
        • van Wijk L.M.
        • et al.
        Frequent homologous recombination deficiency in high-grade endometrial carcinomas.
        Clin Cancer Res. 2019; 25: 1087-1097
        • Vermij L.
        • Smit V.
        • Nout R.
        • Bosse T.
        Incorporation of molecular characteristics into endometrial cancer management.
        Histopathology. 2020; 76: 52-63
        • De Felice F.
        • Marchetti C.
        • Tombolini V.
        • Panici P.B.
        Immune check-point in endometrial cancer.
        Int J Clin Oncol. 2019; 24: 910-916
        • Robert C.
        A decade of immune-checkpoint inhibitors in cancer therapy.
        Nat Commun. 2020; 11: 3801
        • Marcus L.
        • Lemery S.J.
        • Keegan P.
        • Pazdur R.
        FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors.
        Clin Cancer Res. 2019; 25: 3753-3758
        • Musacchio L.
        • Boccia S.M.
        • Caruso G.
        • et al.
        Immune checkpoint inhibitors: a promising choice for endometrial cancer patients?.
        J Clin Med. 2020; 9: 1721
        • Wiggans AJ
        • Cass GK
        • Bryant A
        • Lawrie TA
        • Morrison J
        Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
        Cochrane Database Syst Rev. 2015; : CD007929https://doi.org/10.1002/14651858.CD007929.pub3
        • Dedes KJ
        • Wetterskog D
        • Mendes-Pereira AM
        • et al.
        PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
        Sci Transl Med. 2010; 2: 53ra75
        • Gentry-Maharaj A.
        • Karpinskyj C.
        Current and future approaches to screening for endometrial cancer.
        Best Pract Res Clin Obstet Gynaecol. 2020; 65: 79-97
        • Long B.
        • Clarke M.A.
        • Morillo A.D.M.
        • Wentzensen N.
        • Bakkum-Gamez J.N.
        Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: systematic review and meta-analysis.
        Gynecol Oncol. 2020; 157: 624-633
        • Breijer M.C.
        • Peeters J.A.
        • Opmeer B.C.
        • et al.
        Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis.
        Ultrasound Obstet Gynecol. 2012; 40: 621-629
        • van Hanegem N.
        • Prins M.M.
        • Bongers M.Y.
        • et al.
        The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis.
        Eur J Obstet Gynecol Reprod Biol. 2016; 197: 147-155
        • Ryan N.A.J.
        • McMahon R.F.T.
        • Ramchander N.C.
        • Seif M.W.
        • Evans D.G.
        • Crosbie E.J.
        Lynch syndrome for the gynaecologist.
        Obstetr Gynaecol. 2021; 23: 9-20
        • Dominguez-Valentin M.
        • Sampson J.R.
        • Seppala T.T.
        • et al.
        Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
        Genet Med. 2020; 22: 15-25
        • Ryan N.A.J.
        • Morris J.
        • Green K.
        • et al.
        Association of mismatch repair mutation with age at cancer onset in lynch syndrome: implications for stratified surveillance strategies.
        JAMA Oncol. 2017; 3: 1702-1706
        • Ryan N
        • Nobes M
        • Sedgewick D
        • Teoh SN
        • Evans DG
        • Crosbie EJ
        A mismatch in care: results of a United Kingdom-wide patient and clinician survey of gynaecological services for women with Lynch syndrome.
        BJOG. 2021; 128: 728-736https://doi.org/10.1111/1471-0528.16432
        • Funston G.
        • O'Flynn H.
        • Ryan N.A.J.
        • Hamilton W.
        • Crosbie E.J.
        Correction to: recognizing gynecological cancer in primary care: risk factors, red flags, and referrals.
        Adv Ther. 2018; 35: 590
        • Funston G.
        • O'Flynn H.
        • Ryan N.A.J.
        • Hamilton W.
        • Crosbie E.J.
        Recognizing gynecological cancer in primary care: risk factors, red flags, and referrals.
        Adv Ther. 2018; 35: 577-589
      4. National Institute for Health and Care Excellence. NICE guidelines (NG12) Suspected cancer: recognition and referral. June 2015, update Sep 2020; Available at: https://www.nice.org.uk/guidance/ng12. 2020.

        • Burstein H.J.
        • Temin S.
        • Anderson H.
        • et al.
        Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update.
        J Clin Oncol. 2014; 32: 2255-2269
        • Fisher B.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Gerber B.
        • Krause A.
        • Muller H.
        • et al.
        Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
        J Clin Oncol. 2000; 18: 3464-3470
        • Mackintosh M.L.
        • Crosbie E.J.
        Obesity-driven endometrial cancer: is weight loss the answer?.
        BJOG. 2013; 120: 791-794
        • Crosbie E.J.
        • Zwahlen M.
        • Kitchener H.C.
        • Egger M.
        • Renehan A.G.
        Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis.
        Cancer Epidemiol Biomarkers Prev. 2010; 19: 3119-3130
        • Renehan A.G.
        • Soerjomataram I.
        • Tyson M.
        • et al.
        Incident cancer burden attributable to excess body mass index in 30 European countries.
        Int J Cancer. 2010; 126: 692-702
        • Anveden A.
        • Taube M.
        • Peltonen M.
        • et al.
        Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study.
        Gynecol Oncol. 2017; 145: 224-229
        • Luo J.
        • Chlebowski R.T.
        • Hendryx M.
        • et al.
        Intentional weight loss and endometrial cancer risk.
        J Clin Oncol. 2017; 35: 1189-1193
        • Ward K.K.
        • Roncancio A.M.
        • Shah N.R.
        • et al.
        Bariatric surgery decreases the risk of uterine malignancy.
        Gynecol Oncol. 2014; 133: 63-66
        • Schmid D.
        • Behrens G.
        • Keimling M.
        • Jochem C.
        • Ricci C.
        • Leitzmann M.
        A systematic review and meta-analysis of physical activity and endometrial cancer risk.
        Eur J Epidemiol. 2015; 30: 397-412
      5. World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Food, nutrition, physical activity, and the prevention of cancer: a global perspective Washington DC: AICR; 2007.

      6. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580 e1- e9.

      7. Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UK-MEC 2016). London, UK; 2016.

        • Jareid M.
        • Thalabard J.C.
        • Aarflot M.
        • Bovelstad H.M.
        • Lund E.
        • Braaten T.
        Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
        Gynecol Oncol. 2018; 149: 127-132
        • Schmeler K.M.
        • Lynch H.T.
        • Chen L.M.
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        N Engl J Med. 2006; 354: 261-269
        • Dominguez-Valentin M.
        • Crosbie E.J.
        • Engel C.
        • et al.
        Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
        Genet Med. 2021; 23: 705-712https://doi.org/10.1038/s41436-020-01029-1
        • Chlebowski R.T.
        • Wactawski-Wende J.
        • Ritenbaugh C.
        • et al.
        Estrogen plus progestin and colorectal cancer in postmenopausal women.
        N Engl J Med. 2004; 350: 991-1004
        • Kingsberg S.A.
        • Larkin L.C.
        • Liu J.H.
        Clinical effects of early or surgical menopause.
        Obstet Gynecol. 2020; 135: 853-868
        • Burn J.
        • Sheth H.
        • Elliott F.
        • et al.
        Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
        Lancet. 2020; 395: 1855-1863
        • Lu K.H.
        • Loose D.S.
        • Yates M.S.
        • et al.
        Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.
        Cancer Prev Res (Phila). 2013; 6: 774-781
      8. Available at 2020 https://www.rcog.org.uk/globalassets/documents/guidelines/2020-05-21-joint-rcog-bsge-bgcs-guidance-for-management-of-abnormal-uterine-bleeding-aub-in-the-evolving-coronavirus-covid-19-pandemic-updated-final-180520.pdf.

      9. National Institute for Health and Care Excellence. NICE guidelines (NG88) Heavy menstrual bleeding: assessment and management; 14 March 2018; https://www.nice.org.uk/guidance/ng88. 2018.

        • Gredmark T.
        • Kvint S.
        • Havel G.
        • Mattsson L.A.
        Histopathological findings in women with postmenopausal bleeding.
        BJOG. 1995; 102: 133-136
        • Clarke M.A.
        • Long B.J.
        • Del Mar M.A.
        • Arbyn M.
        • Bakkum-Gamez J.N.
        • Wentzensen N.
        Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis.
        JAMA Intern Med. 2018; 178: 1210-1222
        • Burton E.R.
        • Sorosky J.I.
        Recognition and therapeutic options for malignancy of the cervix and uterus.
        Obstet Gynecol Clin North Am. 2017; 44: 195-206
        • Dijkhuizen F.P.
        • Mol B.W.
        • Brolmann H.A.
        • Heintz A.P.
        Cost-effectiveness of the use of transvaginal sonography in the evaluation of postmenopausal bleeding.
        Maturitas. 2003; 45: 275-282
        • Gull B.
        • Karlsson B.
        • Milsom I.
        • Granberg S.
        Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer.
        Am J Obstet Gynecol. 2003; 188: 401-408
        • Rossi A.
        • Forzano L.
        • Romanello I.
        • Fachechi G.
        • Marchesoni D.
        Assessment of endometrial volume and vascularization using transvaginal 3D power Doppler angiography in women with postmenopausal bleeding.
        Int J Gynaecol Obstet. 2012; 119: 14-17
        • Gupta J.K.
        • Chien P.F.
        • Voit D.
        • Clark T.J.
        • Khan K.S.
        Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis.
        Acta Obstet Gynecol Scand. 2002; 81: 799-816
        • Timmermans A.
        • Opmeer B.C.
        • Khan K.S.
        • et al.
        Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis.
        Obstet Gynecol. 2010; 116: 160-167
        • Wong A.S.
        • Lao T.T.
        • Cheung C.W.
        • et al.
        Reappraisal of endometrial thickness for the detection of endometrial cancer in postmenopausal bleeding: a retrospective cohort study.
        BJOG. 2016; 123: 439-446
        • Jones E.R.
        • O’Flynn H.
        • Njoku K.
        • Crosbie E.J.
        Detecting endometrial cancer.
        Obstetr Gynaecol. 2021; 23: 103-112
        • Doll K.M.
        • Romano S.S.
        • Marsh E.E.
        • Robinson W.R.
        Estimated performance of transvaginal ultrasonography for evaluation of postmenopausal bleeding in a simulated cohort of black and white women in the US.
        JAMA Oncol. 2021; 7: 1158-1165
        • Smith-Bindman R.
        • Kerlikowske K.
        • Feldstein V.A.
        • et al.
        Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities.
        JAMA. 1998; 280: 1510-1517
        • Ghoubara AA-O
        • Emovon E
        • Sundar S
        • Ewies A
        Thickened endometrium in asymptomatic postmenopausal women - determining an optimum threshold for prediction of atypical hyperplasia and cancer.
        J Obstet Gynecol. 2018; 38: 1146-1149
        • Gambacciani M.
        • Monteleone P.
        • Ciaponi M.
        • Sacco A.
        • Genazzani A.R.
        Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women.
        Maturitas. 2004; 48: 421-424
        • van Hanegem N.
        • Breijer M.C.
        • Slockers S.A.
        • et al.
        Diagnostic workup for postmenopausal bleeding: a randomised controlled trial.
        BJOG. 2017; 124: 231-240
        • Clark T.J.
        • Mann C.H.
        • Shah N.
        • Khan K.S.
        • Song F.
        • Gupta J.K.
        Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review.
        BJOG. 2002; 109: 313-321
        • Clark T.J.
        • Voit D.
        • Gupta J.K.
        • Hyde C.
        • Song F.
        • Khan K.S.
        Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review.
        JAMA. 2002; 288: 1610-1621
        • Sainz de la Cuesta R.
        • Espinosa J.A.
        • Crespo E.
        • Granizo J.J.
        • Rivas F.
        Does fluid hysteroscopy increase the stage or worsen the prognosis in patients with endometrial cancer? A randomized controlled trial.
        Eur J Obstet Gynecol Reprod Biol. 2004; 115: 211-215
      10. Royal College of Obstetricians & Gynaecologists- The distal fallopian tube as the origin of non-uterine pelvic high grade serous carcinomas. Scientific impact paper No. 44, Nov 2014:2-8. 2014.

      11. NHS Cancer Plan. In: Department of Health, editor. London, UK 2000.

      12. Cancer Reform Strategy. In: Department of Health, editor. London, UK 2007.

      13. The NHS Long Term Plan. In: Department of Health and Social Care, editor. 2019.

      14. Welsh Government/Llywodraeth Cymru. The quality statement for cancer. Cardiff, UK: Welsh Government/Llywodraeth Cymru; 2021.

      15. NHS standard contract for complex gynaecology - specialist gynaecological cancers. Schedule 2- The Services A. Service Specifications. In: NHS England, editor. 2013.

      16. Guidance on Commissioning Cancer Services. Improving Outcomes in Gynaecological Cancers. The Manual. NHS Executive Catalogue No 16149, July 1999.

      17. Cook O, McIntyre M Fau - Recoche K, Recoche K. Exploration of the role of specialist nurses in the care of women with gynaecological cancer: a systematic review. (1365-2702 (Electronic)).

      18. Macmillan Cancer Support. Cancer Clinical Nurse Specialists. 2015.

      19. Buckley L, Robertson S, Wilson T, Sharpless J, Bolton S. The Role of the Specialist Nurse in Gynaecological Cancer. (1534-6269 (Electronic)).

        • Adedayo P.
        • Resnick K.
        • Singh S.
        Preoperative frailty is a risk factor for non-home discharge in patients undergoing surgery for endometrial cancer.
        J Geriatr Oncol. 2018; 9: 513-515
        • Driver J.A.
        • Viswanathan A.N.
        Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older.
        Gynecol Oncol. 2017; 145: 526-530
        • Martin F.E.
        • Kalsi T.
        • Baker H.
        • et al.
        Functional recovery in older women undergoing surgery for gynaecological malignancies: A systematic review and narrative synthesis.
        J Geriatr Oncol. 2020; 11: 1087-1095
        • Santhirapala R.
        • Partridge J.
        • MacEwen C.J.
        The older surgical patient - to operate or not? A state of the art review.
        Anaesthesia. 2020; 75: e46-e53
        • Aitken R.M.
        • Partridge J.S.L.
        • Oliver C.M.
        • et al.
        Older patients undergoing emergency laparotomy: observations from the National Emergency Laparotomy Audit (NELA) years 1–4.
        Age Ageing. 2020; 49: 656-663
        • Connor J.P.
        • Andrews J.I.
        • Anderson B.
        • Buller R.E.
        Computed tomography in endometrial carcinoma.
        Obstet Gynecol. 2000; 95: 692-696
        • Milam M.R.
        • Java J.
        • Walker J.L.
        • et al.
        Nodal metastasis risk in endometrioid endometrial cancer.
        Obstet Gynecol. 2012; 119: 286-292
        • Selman T.J.
        • Mann C.H.
        • Zamora J.
        • Khan K.S.
        A systematic review of tests for lymph node status in primary endometrial cancer.
        BMC Womens Health. 2008; 8: 8
        • Rockall A.G.
        • Cross S.
        • Flanagan S.
        • Moore E.
        • Avril N.
        The role of FDG-PET/CT in gynaecological cancers.
        Cancer Imaging. 2012; 12: 49-65
        • Narayanan P.
        • Sahdev A.
        The role of (18)F-FDG PET CT in common gynaecological malignancies.
        Br J Radiol. 2017; 90: 20170283
      20. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016;26(1):2-30.

        • Ganesan R
        • Singh N
        • McCluggage WG
        Dataset for histological reporting of endometrial cancer. The Royal College of Pathologists, London, UK2020
        • Trimble C.L.
        • Kauderer J.
        • Zaino R.
        • et al.
        Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
        Cancer. 2006; 106: 812-819
        • Malpica A.
        • Euscher E.D.
        • Hecht J.L.
        • et al.
        Endometrial carcinoma, grossing and processing issues: recommendations of the international society of gynecologic pathologists.
        Int J Gynecol Pathol. 2019; 38: S9-S24
      21. WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon, France; 2020. Available from: https://publications.iarc.fr/592.

        • Bokhman Ia V.
        • Vishnevskii A.S.
        2 pathogenetic variants of corpus uteri cancer.
        Akush Ginekol (Mosk). 1984; 4: 34-37
        • Piulats J.M.
        • Guerra E.
        • Gil-Martin M.
        • et al.
        Molecular approaches for classifying endometrial carcinoma.
        Gynecol Oncol. 2017; 145: 200-207
        • Stasenko M.
        • Tunnage I.
        • Ashley C.W.
        • et al.
        Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
        Gynecol Oncol. 2020; 156: 194-202
        • Gilks C.B.
        • Oliva E.
        • Soslow R.A.
        Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.
        Am J Surg Pathol. 2013; 37: 874-881
        • Cho K.R.
        • Cooper K.
        • Croce S.
        • et al.
        International Society of Gynecological Pathologists (ISGyP) endometrial cancer project: guidelines from the special techniques and ancillary studies group.
        Int J Gynecol Pathol. 2019; 38: S114-S122
        • Moller P.
        • Seppala T.
        • Bernstein I.
        • et al.
        Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.
        Gut. 2017; 66: 464-472
        • Khoo C.K.
        • Vickery C.J.
        • Forsyth N.
        • Vinall N.S.
        • Eyre-Brook I.A.
        A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer.
        Ann Surg. 2007; 245: 867-872
        • Sanchez-Iglesias J.L.
        • Carbonell-Socias M.
        • Perez-Benavente M.A.
        • et al.
        PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
        Eur J Cancer. 2020; 136: 149-158
        • Bisch S.P.
        • Jago C.A.
        • Kalogera E.
        • et al.
        Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis.
        Gynecol Oncol. 2021; 161: 46-55
        • Amant F.
        • Mirza M.R.
        • Koskas M.
        • Creutzberg C.L.
        Cancer of the corpus uteri.
        Int J Gynaecol Obstet. 2018; 143: 37-50
        • Jia P.
        • Zhang Y.
        Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer.
        Oncotarget. 2017; 8: 59940-59949
      22. Hanley GE, Kwon JS, McAlpine JN, Huntsman DG, Finlayson SJ, Miller D. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. Am J Obstet Gynecol. 2020;223(2):221 e1- e11.

        • Galaal K
        • Donkers H
        • Bryant A
        • Lopes AD
        Laparoscopy versus laparotomy for the management of early stage endometrial cancer.
        Cochrane Database Syst Rev. 2018; : CD006655https://doi.org/10.1002/14651858.CD006655.pub3
        • Fader A.N.
        • Seamon L.G.
        • Escobar P.F.
        • et al.
        Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.
        Gynecol Oncol. 2012; 126: 180-185
      23. Maenpaa MM, Nieminen K, Tomas EI, Laurila M, Luukkaala TH, Maenpaa JU. Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: a randomized controlled trial. Am J Obstet Gynecol. 2016;215(5):588 e1- e7.

        • Wang J.
        • Li X.
        • Wu H.
        • Zhang Y.
        • Wang F.
        A Meta-analysis of robotic surgery in endometrial cancer: comparison with laparoscopy and laparotomy.
        Dis Markers. 2020; 2020: 2503753
        • Salehi S.
        • Avall-Lundqvist E.
        • Legerstam B.
        • Carlson J.W.
        • Falconer H.
        Robot-assisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer: a randomised controlled trial.
        Eur J Cancer. 2017; 79: 81-89
        • Lawrie TA
        • Liu H
        • Lu D
        • et al.
        Robot-assisted surgery in gynaecology.
        Cochrane Database Syst Rev. 2019; : CD011422https://doi.org/10.1002/14651858.CD011422.pub2
        • Benedetti Panici P.
        • Basile S.
        • Maneschi F.
        • et al.
        Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
        J Natl Cancer Inst. 2008; 100: 1707-1716
        • Kitchener H
        • Swart AM
        • Qian Q
        • Amos C
        • Parmar MK
        • ASTEC Study Group
        Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
        Lancet. 2009; 373: 125-136
        • Frost JA
        • Webster KE
        • Bryant A
        • Morrison J
        Lymphadenectomy for the management of endometrial cancer.
        Cochrane Database Syst Rev. 2017; : CD007585https://doi.org/10.1002/14651858.CD007585.pub3
        • Pigott A.
        • Obermair A.
        • Janda M.
        • et al.
        Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: results from a prospective, longitudinal cohort study.
        Gynecol Oncol. 2020; 158: 375-381
        • Kim S.I.
        • Lim M.C.
        • Lee J.S.
        • et al.
        Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection.
        Eur J Obstet Gynecol Reprod Biol. 2015; 192: 31-36
        • Vargas R.
        • Rauh-Hain J.A.
        • Clemmer J.
        • et al.
        Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis.
        Gynecol Oncol. 2014; 133: 216-220
        • Bristow R.E.
        • Zahurak M.L.
        • Alexander C.J.
        • Zellars R.C.
        • Montz F.J.
        FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
        Int J Gynecol Cancer. 2003; 13: 664-672
        • Chan J.K.
        • Cheung M.K.
        • Huh W.K.
        • et al.
        Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients.
        Cancer. 2006; 107: 1823-1830
        • Cragun J.M.
        • Havrilesky L.J.
        • Calingaert B.
        • et al.
        Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
        J Clin Oncol. 2005; 23: 3668-3675
        • Fotopoulou C.
        • El-Balat A.
        • du Bois A.
        • et al.
        Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer.
        Arch Gynecol Obstet. 2015; 292: 1321-1327
        • Havrilesky L.J.
        • Cragun J.M.
        • Calingaert B.
        • et al.
        Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.
        Gynecol Oncol. 2005; 99: 689-695
        • Persson J.
        • Salehi S.
        • Bollino M.
        • Lonnerfors C.
        • Falconer H.
        • Geppert B.
        Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.
        Eur J Cancer. 2019; 116: 77-85
        • Rossi E.C.
        • Kowalski L.D.
        • Scalici J.
        • et al.
        A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
        Lancet Oncol. 2017; 18: 384-392
        • Sozzi G.
        • Fanfani F.
        • Berretta R.
        • et al.
        Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study - a multicentric analysis of predictors of failed mapping.
        Int J Gynecol Cancer. 2020; 30: 1713-1718
        • Nagar H.
        • Wietek N.
        • Goodall R.J.
        • Hughes W.
        • Schmidt-Hansen M.
        • Morrison J.
        Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.
        Cochrane Database Syst Rev. 2021; : CD013021https://doi.org/10.1002/14651858.CD013021.pub2
        • Fotopoulou C.
        • Ind T.
        • Baldwin P.
        • et al.
        Sentinel lymph node consensus document of the British Gynaecological Cancer Society for endometrial, vulvar, and cervical cancers.
        Int J Gynecol Cancer. 2019; 29: 1348-1350
        • Leitao Jr., M.M.
        • Zhou Q.C.
        • Gomez-Hidalgo N.R.
        • et al.
        Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.
        Gynecol Oncol. 2020; 156: 147-153
        • Gomez-Hidalgo N.R.
        • Ramirez P.T.
        • Ngo B.
        • et al.
        Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis.
        Clin Transl Oncol. 2020; 22: 1272-1279
        • Obermair A.
        • Abu-Rustum N.R.
        Sentinel lymph node mapping in endometrial cancer - areas where further research is needed.
        Int J Gynecol Cancer. 2020; 30: 283-284
        • Chi D.S.
        • Barakat R.R.
        • Palayekar M.J.
        • et al.
        The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology.
        Int J Gynecol Cancer. 2008; 18: 269-273
        • Mariani A.
        • Dowdy S.C.
        • Cliby W.A.
        • et al.
        Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.
        Gynecol Oncol. 2008; 109: 11-18
        • Petousis S.
        • Christidis P.
        • Margioula-Siarkou C.
        • et al.
        Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis.
        Arch Gynecol Obstet. 2020; 302: 249-263
        • Hasegawa T.
        • Furugori M.
        • Kubota K.
        • et al.
        Does the extension of the type of hysterectomy contribute to the local control of endometrial cancer?.
        Int J Clin Oncol. 2019; 24: 1129-1136
        • Nasioudis D.
        • Sakamuri S.
        • Ko E.M.
        • et al.
        Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
        Gynecol Oncol. 2020; 157: 335-339
        • Phelippeau J.
        • Koskas M.
        Impact of radical hysterectomy on survival in patients with stage 2 type1 endometrial carcinoma: a matched cohort study.
        Ann Surg Oncol. 2016; 23: 4361-4367
        • Takano M.
        • Ochi H.
        • Takei Y.
        • et al.
        Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?.
        Br J Cancer. 2013; 109: 1760-1765
        • Liu T.
        • Tu H.
        • Li Y.
        • Liu Z.
        • Liu G.
        • Gu H.
        Impact of radical hysterectomy versus simple hysterectomy on survival of patients with stage 2 endometrial cancer: a meta-analysis.
        Ann Surg Oncol. 2019; 26: 2933-2942
        • Peters 3rd, W.A.
        • Andersen W.A.
        • Thornton Jr., W.N.
        • Morley G.W.
        The selective use of vaginal hysterectomy in the management of adenocarcinoma of the endometrium.
        Am J Obstet Gynecol. 1983; 146: 285-289
        • Podzielinski I.
        • Randall M.E.
        • Breheny P.J.
        • et al.
        Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma.
        Gynecol Oncol. 2012; 124: 36-41
        • Acharya S.
        • Perkins S.M.
        • DeWees T.
        • et al.
        Brachytherapy is associated with improved survival in inoperable stage I endometrial adenocarcinoma: A population-based analysis.
        Int J Radiat Oncol Biol Phys. 2015; 93: 649-657
        • Gannavarapu B.S.
        • Hrycushko B.
        • Jia X.
        • Albuquerque K.
        Upfront radiotherapy with brachytherapy for medically inoperable and unresectable patients with high-risk endometrial cancer.
        Brachytherapy. 2020; 19: 139-145
        • Inciura A.
        • Atkocius V.
        • Juozaityte E.
        • Vaitkiene D.
        Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer.
        J Radiat Res. 2010; 51: 675-681
        • van der Steen-Banasik E.
        • Christiaens M.
        • Shash E.
        • et al.
        Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma.
        Eur J Cancer. 2016; 65: 172-181
        • Yaney A.
        • Healy E.
        • Wald P.
        • et al.
        Toxicity and outcomes associated with high-dose rate brachytherapy for medically inoperable endometrial cancer.
        Brachytherapy. 2021; 20: 368-375
        • Baker W.D.
        • Pierce S.R.
        • Mills A.M.
        • Gehrig P.A.
        • Duska L.R.
        Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
        Gynecol Oncol. 2017; 146: 34-38
        • Smrz SA
        • Calo C
        • Fisher JL
        • Salani R
        An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic.
        Am J Obstet Gynecol. 2021; : 506.e1-506.e8
        • Park J.Y.
        • Kim D.Y.
        • Kim J.H.
        • et al.
        Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
        Eur J Cancer. 2013; 49: 868-874
        • Casadio P.
        • La Rosa M.
        • Alletto A.
        • et al.
        Fertility sparing treatment of endometrial cancer with and without initial infiltration of myometrium: a single center experience.
        Cancers (Basel). 2020; 12: n pag
      24. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266 e1-12.

      25. Westin SN, Fellman B, Sun CC, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021;224(2):191 e1- e15.

        • Masciullo V
        • Trivellizzi N
        • Zannoni G
        • et al.
        Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia-endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrol acetate.
        Am J Obstet Gynecol. 2021; 224: 408-410https://doi.org/10.1016/j.ajog.2020.12.1210
        • Novikova O.V.
        • Nosov V.B.
        • Panov V.A.
        • et al.
        Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
        Gynecol Oncol. 2021; 161: 152-159
        • Wei J.
        • Zhang W.
        • Feng L.
        • Gao W.
        Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
        Medicine (Baltimore). 2017; 96e8034
        • Yang B.Y.
        • Gulinazi Y.
        • Du Y.
        • et al.
        Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
        BJOG. 2020; 127: 848-857
        • Zhang Q.
        • Qi G.
        • Kanis M.J.
        • et al.
        Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.
        Oncotarget. 2017; 8: 57642-57653
        • Obermair A.
        • Baxter E.
        • Brennan D.J.
        • et al.
        Fertility-sparing treatment in early endometrial cancer: current state and future strategies.
        Obstet Gynecol Sci. 2020; 63: 417-431
        • Barr CE
        • Ryan NAJ
        • Derbyshire AE
        • et al.
        Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium.
        Cancer Prev Res (Phila). 2021; 14: 1041-1050
        • Liu M.C.
        • Gardner A.B.
        • Wolford J.E.
        • Tewari K.S.
        Endometrial cancer in the morbidly obese: a review.
        Curr Opin Obstet Gynecol. 2020; 32: 42-50
        • Cho A.
        • Lee S.W.
        • Park J.Y.
        • et al.
        Continued medical treatment for persistent early endometrial cancer in young women.
        Gynecol Oncol. 2021; 160: 413-417
        • Rajkumar S.
        • Nath R.
        • Lane G.
        • Mehra G.
        • Begum S.
        • Sayasneh A.
        Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival.
        Eur J Obstet Gynecol Reprod Biol. 2019; 234: 26-31
        • Shih K.K.
        • Yun E.
        • Gardner G.J.
        • Barakat R.R.
        • Chi D.S.
        • Leitao Jr., M.M.
        Surgical cytoreduction in stage IV endometrioid endometrial carcinoma.
        Gynecol Oncol. 2011; 122: 608-611
        • Solmaz U.
        • Mat E.
        • Dereli M.L.
        • et al.
        Stage-III and -IV endometrial cancer: A single oncology centre review of 104 cases.
        J Obstet Gynaecol. 2016; 36: 81-86
        • Barlin J.N.
        • Puri I.
        • Bristow R.E.
        Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis.
        Gynecol Oncol. 2010; 118: 14-18
        • Eto T.
        • Saito T.
        • Kasamatsu T.
        • et al.
        Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan.
        Gynecol Oncol. 2012; 127: 338-344
        • Guo J
        • Cui X
        • Zhang X
        • Qian H
        • Duan H
        • Zhang Y
        The Clinical Characteristics of Endometrial Cancer With Extraperitoneal Metastasis and the Value of Surgery in Treatment.
        Technol Cancer Res Treat. 2020; 191533033820945784
        • Yoon M.S.
        • Park W.
        • Huh S.J.
        • et al.
        Impact of paraaortic lymphadenectomy for endometrial cancer with positive pelvic lymph nodes: A Korean Radiation Oncology Group study (KROG 13–17).
        Eur J Surg Oncol. 2016; 42: 1497-1505
        • Cosgrove C.M.
        • Cohn D.E.
        • Rhoades J.
        • Felix A.S.
        The prognostic significance of aortic lymph node metastasis in endometrial cancer: potential implications for selective aortic lymph node assessment.
        Gynecol Oncol. 2019; 153: 505-510
        • Rabinovich A.
        Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients.
        Arch Gynecol Obstet. 2016; 293: 47-53
        • Vandenput I.
        • Van Calster B.
        • Capoen A.
        • et al.
        Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?.
        Br J Cancer. 2009; 101: 244-249
        • Wilkinson-Ryan I.
        • Frolova A.I.
        • Liu J.
        • et al.
        Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
        Int J Gynecol Cancer. 2015; 25: 63-68
        • Guimaraes G.C.
        • Baiocchi G.
        • Ferreira F.O.
        • et al.
        Palliative pelvic exenteration for patients with gynecological malignancies.
        Arch Gynecol Obstet. 2011; 283: 1107-1112
        • Aalders J.
        • Abeler V.
        • Kolstad P.
        • Onsrud M.
        Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients.
        Obstet Gynecol. 1980; 56: 419-427
        • Creutzberg C.L.
        • van Putten W.L.
        • Koper P.C.
        • et al.
        Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
        Lancet. 2000; 355: 1404-1411
        • Blake P
        • Swart AM
        • et al.
        • ASTEC Study Group
        Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.
        Lancet. 2009; 373: 137-146
        • Keys H.M.
        • Roberts J.A.
        • Brunetto V.L.
        • et al.
        A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2004; 92: 744-751
        • Kong A.
        • Johnson N.
        • Kitchener H.C.
        • Lawrie T.A.
        Adjuvant radiotherapy for stage I endometrial cancer.
        Cochrane Database Syst Rev. 2012; : CD003916https://doi.org/10.1002/14651858.CD003916.pub3
        • Church D.N.
        • Stelloo E.
        • Nout R.A.
        • et al.
        Prognostic significance of POLE proofreading mutations in endometrial cancer.
        J Natl Cancer Inst. 2014; 107: 402
        • Stelloo E.
        • Nout R.A.
        • Osse E.M.
        • et al.
        Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—combined analysis of the PORTEC Cohorts.
        Clin Cancer Res. 2016; 22: 4215
        • León-Castillo A.
        • de Boer S.M.
        • Powell M.E.
        • et al.
        Molecular Classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy.
        J Clin Oncol. 2020; 38: 3388-3397
        • Wortman B.G.
        • Bosse T.
        • Nout R.A.
        • et al.
        Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial.
        Gynecol Oncol. 2018; 151: 69-75
        • Barney B.M.
        • Petersen I.A.
        • Mariani A.
        • Dowdy S.C.
        • Bakkum-Gamez J.N.
        • Haddock M.G.
        The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
        Int J Radiat Oncol Biol Phys. 2013; 85: 109-115
        • Cham S.
        • Huang Y.
        • Tergas A.I.
        • et al.
        Utility of radiation therapy for early-stage uterine papillary serous carcinoma.
        Gynecol Oncol. 2017; 145: 269-276
        • Donovan E.
        • Reade C.J.
        • Eiriksson L.R.
        • et al.
        Outcomes of adjuvant therapy for stage IA serous endometrial cancer.
        Cureus. 2018; 10e3387
        • Nout R.A.
        • Smit V.T.
        • Putter H.
        • et al.
        Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
        Lancet. 2010; 375: 816-823
        • Qu X.M.
        • Velker V.M.
        • Leung E.
        • et al.
        The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: a multi-institutional pooled analysis.
        Gynecol Oncol. 2018; 149: 283-290
        • Shinde A.
        • Li R.
        • Amini A.
        • et al.
        Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
        Gynecol Oncol. 2018; 151: 82-90
        • Sorbe B.
        • Horvath G.
        • Andersson H.
        • Boman K.
        • Lundgren C.
        • Pettersson B.
        External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma–a prospective randomized study.
        Int J Radiat Oncol Biol Phys. 2012; 82: 1249-1255
        • Sunil R.A.
        • Bhavsar D.
        • Shruthi M.N.
        • et al.
        Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma.
        J Contemp Brachytherapy. 2018; 10: 105-114
        • Wortman B.G.
        • Creutzberg C.L.
        • Putter H.
        • et al.
        Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
        Br J Cancer. 2018; 119: 1067-1074
        • Creutzberg C.L.
        • Nout R.A.
        • Lybeert M.L.
        • et al.
        Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
        Int J Radiat Oncol Biol Phys. 2011; 81: e631-e638
        • Nout R.A.
        • van de Poll-Franse L.V.
        • Lybeert M.L.
        • et al.
        Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial.
        J Clin Oncol. 2011; 29: 1692-1700
        • Scholten A.N.
        • van Putten W.L.
        • Beerman H.
        • et al.
        Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.
        Int J Radiat Oncol Biol Phys. 2005; 63: 834-838
        • Ortoft G.
        • Hansen E.S.
        • Bertelsen K.
        Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study.
        Int J Gynecol Cancer. 2013; 23: 1429-1437
        • Bosse T.
        • Peters E.E.
        • Creutzberg C.L.
        • et al.
        Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–A pooled analysis of PORTEC 1 and 2 trials.
        Eur J Cancer. 2015; 51: 1742-1750
        • Bosse T.
        • Nout R.A.
        • Stelloo E.
        • et al.
        L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
        Eur J Cancer. 2014; 50: 2602-2610
        • van den Heerik A.
        • Horeweg N.
        • Nout R.A.
        • et al.
        PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
        Int J Gynecol Cancer. 2020; 30: 2002-2007
        • McAlpine J.
        • Leon-Castillo A.
        • Bosse T.
        The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
        J Pathol. 2018; 244: 538-549
        • Wortman B.G.
        • Nout R.A.
        • Bosse T.
        • Creutzberg C.L.
        Selecting adjuvant treatment for endometrial carcinoma using molecular risk factors.
        Curr Oncol Rep. 2019; 21: 83
        • Randall M.E.
        • Filiaci V.
        • McMeekin D.S.
        • et al.
        Phase III Trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer.
        J Clin Oncol. 2019; 37: 1810-1818
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • et al.
        Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 295-309
        • Hogberg T.
        • Signorelli M.
        • de Oliveira C.F.
        • et al.
        Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies.
        Eur J Cancer. 2010; 46: 2422-2431
        • Susumu N.
        • Sagae S.
        • Udagawa Y.
        • et al.
        Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
        Gynecol Oncol. 2008; 108: 226-233
        • Kuoppala T.
        • Mäenpää J.
        • Tomas E.
        • et al.
        Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
        Gynecol Oncol. 2008; 110: 190-195
        • Maggi R.
        • Lissoni A.
        • Spina F.
        • et al.
        Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial.
        Br J Cancer. 2006; 95: 266-271
        • Morrow C.P.
        • Bundy B.N.
        • Homesley H.D.
        • et al.
        Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study.
        Gynecol Oncol. 1990; 36: 166-171
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • et al.
        Randomized Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study.
        J Clin Oncol. 2006; 24: 36-44
        • Wolfson A.H.
        • Brady M.F.
        • Rocereto T.
        • et al.
        A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
        Gynecol Oncol. 2007; 107: 177-185
        • Johnson N
        • Bryant A
        • Miles T
        • Hogberg T
        • Cornes P
        Adjuvant chemotherapy for endometrial cancer after hysterectomy.
        Cochrane Database Syst Rev. 2011; : CD003175https://doi.org/10.1002/14651858.CD003175.pub2
        • Matei D.
        • Filiaci V.
        • Randall M.E.
        • et al.
        Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.
        N Engl J Med. 2019; 380: 2317-2326
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • et al.
        Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
        Lancet Oncol. 2019; 20: 1273-1285
        • de Boer S.M.
        • Wortman B.G.
        • Bosse T.
        • et al.
        Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
        Ann Oncol. 2018; 29: 424-430
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • et al.
        Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2016; 17: 1114-1126
        • Blinman P.
        • Mileshkin L.
        • Khaw P.
        • et al.
        Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
        Br J Cancer. 2016; 115: 1179-1185
      26. Mirza MR, Lundgren C, Kridelka F, Ferrero A, Amant F. A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102. Journal of Clinical Oncology. 2014;32(15_suppl):TPS5628-TPS.

        • Ko E.M.
        • Brensinger C.M.
        • Cory L.
        • et al.
        Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
        Gynecol Oncol. 2020; 159: 394-401
        • Xiang M.
        • English D.P.
        • Kidd E.A.
        Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
        Gynecol Oncol. 2019; 154: 487-494
        • Levine D.A.
        • Getz G.
        • Gabriel S.B.
        • et al.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Martin‐Hirsch PPL
        • Bryant A
        • Keep SL
        • Kitchener HC
        • Lilford R
        Adjuvant progestagens for endometrial cancer.
        Cochrane Database Syst Rev. 2011; : CD001040https://doi.org/10.1002/14651858.CD001040.pub2
        • Klopp A.H.
        • Yeung A.R.
        • Deshmukh S.
        • et al.
        Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203.
        J Clin Oncol. 2018; 36: 2538-2544
        • de Lange N.M.
        • Ezendam N.P.M.
        • Kwon J.S.
        • et al.
        Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.
        Curr Oncol. 2019; 26: e226-e232
        • Khouri O.R.
        • Frey M.K.
        • Musa F.
        • et al.
        Neoadjuvant chemotherapy in patients with advanced endometrial cancer.
        Cancer Chemother Pharmacol. 2019; 84: 281-285
        • Bogani G
        • Ditto A
        • Leone Roberti Maggiore U
        • et al.
        Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer.
        Tumori. 2019 Feb; 105: 92-97
        • Fleming G.F.
        • Brunetto V.L.
        • Cella D.
        • et al.
        Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study.
        J Clin Oncol. 2004; 22: 2159-2166
        • Miller D.S.
        • Filiaci V.L.
        • Mannel R.S.
        • et al.
        Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209).
        J Clin Oncol. 2020; 38: 3841-3850
        • Powell M.A.
        • Filiaci V.L.
        • Rose P.G.
        • et al.
        Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
        J Clin Oncol. 2010; 28: 2727-2731
        • Ethier J.-L.
        • Desautels D.N.
        • Amir E.
        • MacKay H.
        Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
        Gynecol Oncol. 2017; 147: 158-166
      27. Thigpen JT, Brady MF, Alvarez RD, et al. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group. Journal of Clinical Oncology. 1999;17(6):1736-.

        • Mileshkin L.
        • Edmondson R.
        • O'Connell R.L.
        • et al.
        Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903.
        Gynecol Oncol. 2019; 154: 29-37
        • Mahantshetty U.
        • Poetter R.
        • Beriwal S.
        • et al.
        IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer.
        Radiother Oncol. 2021; 160: 273-284
        • Gill B.S.
        • Kim H.
        • Houser C.
        • et al.
        Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma.
        Brachytherapy. 2014; 13: 542-547
        • Francis S.R.
        • Ager B.J.
        • Do O.A.
        • et al.
        Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy.
        Gynecol Oncol. 2019; 154: 38-44
        • Creutzberg C.L.
        • van Putten W.L.
        • Koper P.C.
        • et al.
        Survival after relapse in patients with endometrial cancer: results from a randomized trial.
        Gynecol Oncol. 2003; 89: 201-209
        • Jeppesen M.M.
        • Jensen P.T.
        • Gilsa Hansen D.
        • Iachina M.
        • Mogensen O.
        The nature of early-stage endometrial cancer recurrence-a national cohort study.
        Eur J Cancer. 2016; 69: 51-60
      28. National Institute for Health and Care Excellence. Improving supportive and palliative care for adults with cancer 2004 [Available from: https://www.nice.org.uk/guidance/csg4.

        • Bollineni V.R.
        • Ytre-Hauge S.
        • Bollineni-Balabay O.
        • Salvesen H.B.
        • Haldorsen I.S.
        High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature.
        J Nucl Med. 2016; 57: 879-885
        • Kadkhodayan S.
        • Shahriari S.
        • Treglia G.
        • Yousefi Z.
        • Sadeghi R.
        Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature.
        Gynecol Oncol. 2013; 128: 397-404
        • Campagnutta E.
        • Giorda G.
        • De Piero G.
        • et al.
        Surgical treatment of recurrent endometrial carcinoma.
        Cancer. 2004; 100: 89-96
        • Jhingran A.
        • Burke T.W.
        • Eifel P.J.
        Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy.
        Int J Radiat Oncol Biol Phys. 2003; 56: 1366-1372
        • Wylie J.
        • Irwin C.
        • Pintilie M.
        • et al.
        Results of radical radiotherapy for recurrent endometrial cancer.
        Gynecol Oncol. 2000; 77: 66-72
        • Hardarson H.A.
        • Heidemann L.N.
        • dePont C.R.
        • Mogensen O.
        • Jochumsen K.M.
        Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery.
        Gynecol Oncol Rep. 2015; 11: 26-30
        • Shepherd J.H.
        • Ngan H.Y.S.
        • Neven P.
        • Fryatt I.
        • Woodhouse C.R.J.
        • Hendry W.F.
        Multivariate analysis of factors affecting survival in pelvic exenteration.
        Int J Gynecol Cancer. 1994; 4: 361-370
        • Khoury-Collado F.
        • Einstein M.H.
        • Bochner B.H.
        • et al.
        Pelvic exenteration with curative intent for recurrent uterine malignancies.
        Gynecol Oncol. 2012; 124: 42-47
        • Schmidt A.M.
        • Imesch P.
        • Fink D.
        • Egger H.
        Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients.
        Int J Gynecol Cancer. 2016; 26: 716-721
        • Kunos C.A.
        • Brindle J.
        • Waggoner S.
        • et al.
        Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies.
        Front Oncol. 2012; 2: 181
        • Ito M.
        • Kodaira T.
        • Koide Y.
        • et al.
        Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
        BMC Cancer. 2020; 20: 540
        • Seo Y.
        • Kim M.S.
        • Yoo H.J.
        • et al.
        Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: feasibility and complication.
        Asia Pac J Clin Oncol. 2016; 12: e280-e288
        • Bristow R.E.
        • Santillan A.
        • Zahurak M.L.
        • Gardner G.J.
        • Giuntoli 2nd, R.L.
        • Armstrong D.K.
        Salvage cytoreductive surgery for recurrent endometrial cancer.
        Gynecol Oncol. 2006; 103: 281-287
        • Ren Y.
        • Shan B.
        • Shi D.
        • Wang H.
        Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study.
        BMC Cancer. 2014; 14: 135
        • Awtrey C.S.
        • Cadungog M.G.
        • Leitao M.M.
        • et al.
        Surgical resection of recurrent endometrial carcinoma.
        Gynecol Oncol. 2006; 102: 480-488
        • Papadia A.
        • Bellati F.
        • Ditto A.
        • et al.
        Surgical treatment of recurrent endometrial cancer: time for a paradigm shift.
        Ann Surg Oncol. 2015; 22: 4204-4210
        • Miller D
        • Filiaci V
        • Fleming G
        al e. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
        Gynecol Oncol. 2012; 125: 771
        • Ang J.E.
        • Shah R.N.
        • Everard M.
        • et al.
        A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
        Ann Oncol. 2009; 20: 1787-1793
        • Humber C.E.
        • Tierney J.F.
        • Symonds R.P.
        • et al.
        Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
        Ann Oncol. 2007; 18: 409-420
        • Aapro M.S.
        Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
        Ann Oncol. 2003; 14: 441-448
        • Thigpen J.T.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
        J Clin Oncol. 2004; 22: 3902-3908
      29. Meissner M, Walther A. What is the most commonly prescribed treatment for metastatic endometrial cancer in the second line setting in the UK, and how effective is this treatment? NCRI Annual Conference; 6-9 November 2016; Liverpool2016.

        • Muggia F.M.
        • Phase I.I.
        Trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study.
        J Clin Oncol. 2002; 20: 2360-2364
        • Miller DS
        • Blessing JA
        • Lentz SS
        A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study.
        Gynecol Oncol. 2002; 87: 247-251
      30. Millennium Pharmaceuticals Inc. A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer [Available from: https://clinicaltrials.gov/ct2/show/NCT02725268.

      31. Clamp A, Kristeleit RS, Jayson G. Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? (COPELIA) [Available from: https://clinicaltrials.gov/ct2/show/NCT03570437.

        • Marabelle A.
        • Le D.T.
        • Ascierto P.A.
        • et al.
        Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study.
        J Clin Oncol. 2020; 38: 1-10
        • Oaknin A.
        • Tinker A.V.
        • Gilbert L.
        • et al.
        Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial.
        JAMA Oncol. 2020; 6: 1766-1772
        • Makker V.
        • Taylor M.H.
        • Aghajanian C.
        • et al.
        Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
        J Clin Oncol. 2020; 38: 2981-2992
      32. Makker VC, N.; Casado Herráez, A.; et al. A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer Presented March 19, 2021; Virtual2021.

        • Kim J.Y.
        • Kronbichler A.
        • Eisenhut M.
        • et al.
        Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors. A Systematic Review and Meta-Analysis.
        Cancers (Basel). 2019; 11
        • van Weelden WJ
        • Massuger L
        • Enitec
        • Pijnenborg JMA
        • Romano A
        Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review.
        Front Oncol. 2019; 9: 359
      33. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010(12):CD007926. https://doi.org/10.1002/14651858.CD007926.pub2.

        • Fiorica J.V.
        • Brunetto V.L.
        • Hanjani P.
        • et al.
        Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2004; 92: 10-14
        • Singh M.
        • Zaino R.J.
        • Filiaci V.J.
        • Leslie K.K.
        Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
        Gynecol Oncol. 2007; 106: 325-333
        • Thigpen J.T.
        • Brady M.F.
        • Homesley H.D.
        • Soper J.T.
        • Bell J.
        Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        J Clin Oncol. 2001; 19: 364-367
        • Ma B.B.
        • Oza A.
        • Eisenhauer E.
        • et al.
        The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group.
        Int J Gynecol Cancer. 2004; 14: 650-658
        • Rose P.G.
        • Brunetto V.L.
        • VanLe L.
        • Bell J.
        • Walker J.L.
        • Lee R.B.
        A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2000; 78: 212-216
      34. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269.

        • Conklin C.M.
        • Longacre T.A.
        Endometrial stromal tumors: the new WHO classification.
        Adv Anat Pathol. 2014; 21: 383-393
      35. Soft Tissue and Bone Tumours. WHO Classification of Tumours 2020.

        • Francis M.
        • Dennis N.L.
        • Hirschowitz L.
        • et al.
        Incidence and survival of gynecologic sarcomas in England.
        Int J Gynecol Cancer. 2015; 25: 850-857
        • Grimer R.
        • Judson I.
        • Peake D.
        • Seddon B.
        Guidelines for the management of soft tissue sarcomas.
        Sarcoma. 2010; 2010506182
        • D'Angelo E.
        • Prat J.
        Uterine sarcomas: a review.
        Gynecol Oncol. 2010; 116: 131-139
        • Giuntoli 2nd, R.L.
        • Metzinger D.S.
        • DiMarco C.S.
        • et al.
        Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
        Gynecol Oncol. 2003; 89: 460-469
        • Parker W.H.
        • Fu Y.S.
        • Berek J.S.
        Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
        Obstet Gynecol. 1994; 83: 414-418
        • Major F.J.
        • Blessing J.A.
        • Silverberg S.G.
        • et al.
        Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study.
        Cancer. 1993; 71: 1702-1709
        • Zivanovic O.
        • Leitao M.M.
        • Iasonos A.
        • et al.
        Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and American joint committee on cancer staging systems.
        J Clin Oncol. 2009; 27: 2066-2072
        • Iasonos A.
        • Keung E.Z.
        • Zivanovic O.
        • et al.
        External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
        Cancer. 2013; 119: 1816-1822
      36. Leibsohn S, d'Ablaing G, Mishell DR, Jr., Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162(4):968-74; discussion 74-6.

        • Leitao M.M.
        • Sonoda Y.
        • Brennan M.F.
        • Barakat R.R.
        • Chi D.S.
        Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.
        Gynecol Oncol. 2003; 91: 209-212
        • Kapp D.S.
        • Shin J.Y.
        • Chan J.K.
        Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
        Cancer. 2008; 112: 820-830
        • Wright J.D.
        • Tergas A.I.
        • Burke W.M.
        • et al.
        Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.
        JAMA. 2014; 312: 1253-1255
        • Zapardiel I
        • Boria F
        • Halaska MJ
        • De Santiago J
        Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread.
        J Minim Invasive Gynecol. 2021; 28: 1442-1443
        • Bogani G.
        • Cliby W.A.
        • Aletti G.D.
        Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.
        Gynecol Oncol. 2015; 137: 167-172
        • George S.
        • Barysauskas C.
        • Serrano C.
        • et al.
        Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
        Cancer. 2014; 120: 3154-3158
      37. Food and Drug Administration. Product Labeling for Laparoscopic Power Morcellators. In: Food and Drug Administration, editor. Rockville, MD2020.

        • Oduyebo T.
        • Rauh-Hain A.J.
        • Meserve E.E.
        • et al.
        The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
        Gynecol Oncol. 2014; 132: 360-365
        • Reed N.S.
        • Mangioni C.
        • Malmstrom H.
        • et al.
        Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
        Eur J Cancer. 2008; 44: 808-818
        • Omura G.A.
        • Blessing J.A.
        • Major F.
        • et al.
        A randomized clinical trial of adjuvant Adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
        J Clin Oncol. 1985; 3: 1240-1245
        • Hensley M.L.
        • Ishill N.
        • Soslow R.
        • et al.
        Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study.
        Gynecol Oncol. 2009; 112: 563-567
        • Littell R.D.
        • Tucker L.Y.
        • Raine-Bennett T.
        • et al.
        Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes.
        Gynecol Oncol. 2017; 147: 11-17
        • Hensley M.L.
        • Wathen J.K.
        • Maki R.G.
        • et al.
        Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
        Cancer. 2013; 119: 1555-1561
        • Hensley ML
        • Enserro D
        • Hatcher H
        • et al.
        Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
        J Clin Oncol. 2018; 36: 3324-3330
        • Leitao Jr., M.M.
        • Zivanovic O.
        • Chi D.S.
        • et al.
        Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
        Gynecol Oncol. 2012; 125: 409-413
        • Park J.Y.
        • Kim D.Y.
        • Suh D.S.
        • et al.
        Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007.
        J Cancer Res Clin Oncol. 2008; 134: 1277-1287
        • Sagae S.
        • Yamashita K.
        • Ishioka S.
        • et al.
        Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.
        Oncology. 2004; 67: 33-39
      38. Dinh TA, Oliva EA, Fuller AF, Jr., Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92(2):648-52.

        • Seddon B.
        • Strauss S.J.
        • Whelan J.
        • et al.
        Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
        Lancet Oncol. 2017; 18: 1397-1410
        • Henry R.
        • Hartley B.
        • Simpson M.
        • Doyle N.
        The development and evaluation of a holistic needs assessment and care planning learning package targeted at cancer nurses in the UK.
        Ecancermedicalscience. 2014; 8: 416
        • Hensley M.L.
        • Blessing J.A.
        • Degeest K.
        • Abulafia O.
        • Rose P.G.
        • Homesley H.D.
        Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
        Gynecol Oncol. 2008; 109: 323-328
        • Hensley M.L.
        • Miller A.
        • O'Malley D.M.
        • et al.
        A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): A Gynecologic Oncology Group study.
        Gynecol Oncol. 2014; 133: 3
        • Tap W.D.
        • Jones R.L.
        • Van Tine B.A.
        • et al.
        Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
        Lancet. 2016; 388: 488-497
        • Tap W.D.
        • Wagner A.J.
        • Schoffski P.
        • et al.
        Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial.
        JAMA. 2020; 323: 1266-1276
        • Pautier P.
        • Floquet A.
        • Chevreau C.
        • et al.
        Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
        Lancet Oncol. 2015; 16: 457-464
        • Martin-Broto J.
        • Pousa A.L.
        • de Las P.R.
        • et al.
        Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A Spanish Group for Research on Sarcoma Study.
        J Clin Oncol. 2016; 34: 2294-2302
        • O'Cearbhaill R.
        • Zhou Q.
        • Iasonos A.
        • et al.
        Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
        Gynecol Oncol. 2010; 116: 424-429
        • Chiang S.
        • Ali R.
        • Melnyk N.
        • et al.
        Frequency of known gene rearrangements in endometrial stromal tumors.
        Am J Surg Pathol. 2011; 35: 1364-1372
        • Chan J.K.
        • Kawar N.M.
        • Shin J.Y.
        • et al.
        Endometrial stromal sarcoma: a population-based analysis.
        Br J Cancer. 2008; 99: 1210-1215
        • Amant F.
        • Floquet A.
        • Friedlander M.
        • et al.
        Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.
        Int J Gynecol Cancer. 2014; 24: S67-S72
        • Nasioudis D.
        • Mastroyannis S.A.
        • Latif N.A.
        • et al.
        Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis.
        Gynecol Oncol. 2020; 157: 634-638
        • Nasioudis D.
        • Ko E.M.
        • Kolovos G.
        • Vagios S.
        • Kalliouris D.
        • Giuntoli R.L.
        Ovarian preservation for low-grade endometrial stromal sarcoma: a systematic review of the literature and meta-analysis.
        Int J Gynecol Cancer. 2019; 29: 126-132
        • Laurelli G.
        • Falcone F.
        • Scaffa C.
        • et al.
        Fertility-sparing management of low-grade endometrial stromal sarcoma: analysis of an institutional series and review of the literature.
        Eur J Obstet Gynecol Reprod Biol. 2015; 195: 61-66
        • Chu M.C.
        • Mor G.
        • Lim C.
        • Zheng W.
        • Parkash V.
        • Schwartz P.E.
        Low-grade endometrial stromal sarcoma: hormonal aspects.
        Gynecol Oncol. 2003; 90: 170-176
        • Rauh-Hain J.A.
        • del Carmen M.G.
        Endometrial stromal sarcoma: a systematic review.
        Obstet Gynecol. 2013; 122: 676-683
        • Deshmukh U.
        • Black J.
        • Perez-Irizarry J.
        • et al.
        Adjuvant hormonal therapy for low-grade endometrial stromal sarcoma.
        Reprod Sci. 2019; 26: 600-608
        • Pink D.
        • Lindner T.
        • Mrozek A.
        • et al.
        Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
        Gynecol Oncol. 2006; 101: 464-469
        • Carroll A.
        • Ramirez P.T.
        • Westin S.N.
        • et al.
        Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.
        Gynecol Oncol. 2014; 135: 455-461
        • Tanner E.J.
        • Toussaint T.
        • Leitao Jr, M.M.
        • et al.
        Management of uterine adenosarcomas with and without sarcomatous overgrowth.
        Gynecol Oncol. 2013; 129: 140-144
      39. Department of Health. Hospital Episodes Statistics 2010 [Available from: http://www.hesonline.nhs.uk].

        • Gadducci A.
        • Cosio S.
        • Fanucchi A.
        • Cristofani R.
        • Genazzani A.R.
        An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
        Anticancer Res. 2000; 20: 1977-1984
        • Agboola O.O.
        • Grunfeld E.
        • Coyle D.
        • Perry G.A.
        Costs and benefits of routine follow-up after curative treatment for endometrial cancer.
        CMAJ. 1997; 157: 879-886
        • Allsop J.R.
        • Preston J.
        • Crocker S.
        Is there any value in the long-term follow up of women treated for endometrial cancer?.
        Br J Obstet Gynaecol. 1997; 104: 122
        • Owen P.
        • Duncan I.D.
        Is there any value in the long term follow up of women treated for endometrial cancer?.
        Br J Obstet Gynaecol. 1996; 103: 710-713
        • Salvesen H.B.
        • Akslen L.A.
        • Iversen T.
        • Iversen O.E.
        Recurrence of endometrial carcinoma and the value of routine follow up.
        Br J Obstet Gynaecol. 1997; 104: 1302-1307
        • Fung-Kee-Fung M.
        • Dodge J.
        • Elit L.
        • et al.
        Follow-up after primary therapy for endometrial cancer: a systematic review.
        Gynecol Oncol. 2006; 101: 520-529
        • Sperling C.
        • Sandager M.
        • Jensen H.
        • Knudsen J.L.
        Current organisation of follow-up does not meet cancer patients' needs.
        Dan Med J. 2014; 61: A4855
        • Kew F.M.
        • Cruickshank D.J.
        Routine follow-up after treatment for a gynecological cancer: a survey of practice.
        Int J Gynecol Cancer. 2006; 16: 380-384
      40. Department of Health. Improving outcomes: a strategy for cancer. In: Department of Health, editor. London2011.

        • Newton C NA
        • Rolland P
        • Ind T
        • Larson-Disney P
        • Martin-Hirsch P
        • Beaver K
        • et al.
        British Gynaecology Cancer Society recommendations and guidance on patient-initiated follow up (PIFU).
        Int J Gynecol Cancer. 2020; 30: 695-700
        • Watson E.K.
        • Rose P.W.
        • Neal R.D.
        • et al.
        Personalised cancer follow-up: risk stratification, needs assessment or both?.
        Br J Cancer. 2012; 106: 1-5
        • Coleman L.
        • Newton C.
        Patient initiated follow up after gynaecological malignancy: National survey of current UK practice.
        Eur J Obstet Gynecol Reprod Biol. 2020; 248: 193-197
        • Leeson S.
        • Stuart N.
        • Sylvestre Y.
        • Hall L.
        • Whitaker R.
        Gynaecological cancer follow-up: national survey of current practice in the UK.
        BMJ Open. 2013; 3: e002859
        • Nordin A.J.
        National Group of Gynaecology NL. Mode of detection of recurrent gynecological malignancy: does routine follow-up delay diagnosis and treatment?.
        Int J Gynecol Cancer. 2006; 16: 1746-1748
        • Vistad I.
        • Bjorge L.
        • Solheim O.
        • et al.
        A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway.
        Acta Obstet Gynecol Scand. 2017; 96: 1162-1169
      41. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41.

      42. ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102-12.

      43. Macmillan Cancer Support. Providing personalised care for people living with cancer 2019.(https://www.macmillan.org.uk/_images/providing-personalised-care-for-people-living-with-cancer_tcm9-355674.pdf).

      44. Macmillan Cancer Support. Clinical Nurse Specialists an evidence review. 2012.(https://www.macmillan.org.uk/_images/Clinical-Nurse-Specialists_tcm9-283175.pdf).

        • Holmes L.
        • Miles T.
        • White I.
        Female sexual health after a cancer diagnosis.
        Cancer Nursing Practice. 2015; 14: 16-22
        • Aerts L.
        • Enzlin P.
        • Verhaeghe J.
        • Poppe W.
        • Vergote I.
        • Amant F.
        Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study.
        J Sex Med. 2015; 12: 198-209
        • Ferguson S.E.
        • Panzarella T.
        • Lau S.
        • et al.
        Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer.
        Gynecol Oncol. 2018; 149: 476-483
        • Damast S.
        • Alektiar K.M.
        • Goldfarb S.
        • et al.
        Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy.
        Int J Radiat Oncol Biol Phys. 2012; 84: e187-e193
        • Miles T
        • Johnson N
        Vaginal dilator therapy for women receiving pelvic radiotherapy.
        Cochrane Database Syst Rev. 2014; CD007291https://doi.org/10.1002/14651858.CD007291.pub3
        • White I.D.
        • Tennant A.
        • Taylor C.
        Sexual Morbidity assessment in gyne-oncology follow-up: development of the sexual well-being after cervical or endometrial cancer (SWELL-CE) patient-reported outcome measure.
        J Sex Med. 2020; 17: 2005-2015
        • Flynn P
        • Kew F
        • Kisely SR
        Interventions for psychosexual dysfunction in women treated for gynaecological malignancy.
        Cochrane Database Syst Rev. 2009; CD004708https://doi.org/10.1002/14651858.CD004708.pub2
      45. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5:CD008830. https://doi.org/10.1002/14651858.CD008830.pub3.

        • Gu H.
        • Li J.
        • Gu Y.
        • Tu H.
        • Zhou Y.
        • Liu J.
        Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis.
        Int J Gynecol Cancer. 2017; 27: 77-84
        • Hou T.
        • Sun Y.
        • Li J.
        • et al.
        The Safety of Ovarian Preservation in Stage I endometrial endometrioid adenocarcinoma based on propensity score matching.
        Comb Chem High Throughput Screen. 2017; 20: 647-655
        • Lau H.Y.
        • Chen M.Y.
        • Ke Y.M.
        • et al.
        Outcome of ovarian preservation during surgical treatment for endometrial cancer: a Taiwanese Gynecologic Oncology Group study.
        Taiwan J Obstet Gynecol. 2015; 54: 532-536
        • Lau H.Y.
        • Twu N.F.
        • Yen M.S.
        • et al.
        Impact of ovarian preservation in women with endometrial cancer.
        J Chin Med Assoc. 2014; 77: 379-384
        • Lee T.S.
        • Lee J.Y.
        • Kim J.W.
        • et al.
        Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study.
        Gynecol Oncol. 2013; 131: 289-293
        • Lyu T.
        • Guo L.
        • Chen X.
        • et al.
        Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study.
        J Int Med Res. 2019; 47: 2492-2498
        • Wright J.D.
        • Buck A.M.
        • Shah M.
        • Burke W.M.
        • Schiff P.B.
        • Herzog T.J.
        Safety of ovarian preservation in premenopausal women with endometrial cancer.
        J Clin Oncol. 2009; 27: 1214-1219
        • Brennan A.
        • Brennan D.
        • Rees M.
        • Hickey M.
        Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
        Int J Gynecol Cancer. 2021; 31: 352-359
        • Hareyama H.
        • Hada K.
        • Goto K.
        • et al.
        Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study.
        Int J Gynecol Cancer. 2015; 25: 751-757
        • Hayes S.C.
        • Janda M.
        • Ward L.C.
        • et al.
        Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors.
        Gynecol Oncol. 2017; 146: 623-629
        • Lindqvist E.
        • Wedin M.
        • Fredrikson M.
        • Kjolhede P.
        Lymphedema after treatment for endometrial cancer - A review of prevalence and risk factors.
        Eur J Obstet Gynecol Reprod Biol. 2017; 211: 112-121
        • Mitra D.
        • Catalano P.J.
        • Cimbak N.
        • Damato A.L.
        • Muto M.G.
        • Viswanathan A.N.
        The risk of lymphedema after postoperative radiation therapy in endometrial cancer.
        J Gynecol Oncol. 2016; 27e4
        • Yost K.J.
        • Cheville A.L.
        • Al-Hilli M.M.
        • et al.
        Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life.
        Obstet Gynecol. 2014; 124: 307-315
      46. Macmillan Cancer Support. Part 1: Guidelines on Late Effects of Gynaecological Cancer: Pelvic Radiotherapy. London; 2014.

        • Newton C.
        • Nordin A.
        • Rolland P.
        • et al.
        British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU).
        Int J Gynecol Cancer. 2020; 30: 695-700
        • van Walree I.C.
        • Hamaker M.E.
        • de Rooij B.H.
        • et al.
        Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?.
        J Geriatr Oncol. 2020; 11: 1078-1086
        • de Boer S.M.
        • Nout R.A.
        • Jurgenliemk-Schulz I.M.
        • et al.
        Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.
        Int J Radiat Oncol Biol Phys. 2015; 93: 797-809
        • Post C.C.B.
        • de Boer S.M.
        • Powell M.E.
        • et al.
        Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 Trial.
        Int J Radiat Oncol Biol Phys. 2021; 109: 975-986
      47. Cancer Research UK. Womb Cancer Survival. 2020.

        • Muls A.
        • Taylor A.
        • Lalondrelle S.
        • et al.
        A proposed tailored investigational algorithm for women treated for gynaecological cancer with long-term gastrointestinal consequences.
        Support Care Cancer. 2020; 28: 4881-4889
        • Lawrie TA
        • Green Jt Fau - Beresford M
        • BeresfordFau - Wedlake ML
        • et al.
        Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.
        Cochrane Database Syst Rev. 2018; : CD012529https://doi.org/10.1002/14651858.CD012529.pub2
        • Halkett G.K.B.
        • Wigley C.A.
        • Aoun S.M.
        • et al.
        International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study.
        Radiat Oncol. 2018; 13: 162
        • Taylor S.
        • Byrne A.
        • Adams R.
        • et al.
        The Three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors.
        Clin Oncol (R Coll Radiol). 2016; 28: e139-e147
      48. NHS England. Service Specification No. 170091S; Adult External Beam Radiotherapy Services. In: NHS England, editor. London 2019.

        • Andreyev H.J.
        • Muls A.C.
        • Norton C.
        • et al.
        Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease.
        Frontline Gastroenterol. 2015; 6: 53-72
        • van de Wetering FT
        • Verleye L
        • Andreyev HJ
        • et al.
        Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis.
        Cochrane Database Syst Rev. 2016; 4: CD003455
        • Mege D.
        • Meurette G.
        • Trilling B.
        • et al.
        Efficacy and safety of sacral nerve modulation for faecal incontinence after pelvic radiotherapy.
        Radiother Oncol. 2020; 146: 167-171
        • Soisson S.
        • Ganz P.A.
        • Gaffney D.
        • et al.
        Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
        Gynecol Oncol. 2018; 148: 499-506
        • Segal S.
        • John G.
        • Sammel M.
        • et al.
        Urinary incontinence and other pelvic floor disorders after radiation therapy in endometrial cancer survivors.
        Maturitas. 2017; 105: 83-88
        • Cooper J.
        • Annappa M.
        • Quigley A.
        • Dracocardos D.
        • Bondili A.
        • Mallen C.
        Prevalence of female urinary incontinence and its impact on quality of life in a cluster population in the United Kingdom (UK): a community survey.
        Prim Health Care Res Dev. 2015; 16: 377-382
        • Bosch R.
        • McCloskey K.
        • Bahl A.
        • et al.
        Can radiation-induced lower urinary tract disease be ameliorated in patients treated for pelvic organ cancer: ICI-RS 2019?.
        Neurourol Urodyn. 2020; 39: S148-S155
        • Spampinato S.
        • Tanderup K.
        • Marinovskij E.
        • et al.
        MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy.
        Radiother Oncol. 2020; 145: 117-124
      49. NationalI nstitute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management (NICE guidance [NG123]). In: NICE, editor. London 2019.

        • Pascoe C.
        • Duncan C.
        • Lamb B.W.
        • et al.
        Current management of radiation cystitis: a review and practical guide to clinical management.
        BJU Int. 2019; 123: 585-594
        • Toia B.
        • Seth J.
        • Ecclestone H.
        • et al.
        Outcomes of reconstructive urinary tract surgery after pelvic radiotherapy.
        Scand J Urol. 2019; 53: 156-160
        • Villeirs L.
        • Tailly T.
        • Ost P.
        • et al.
        Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: systematic review of the recent literature.
        Int J Urol. 2020; 27: 98-107
        • Baxter N.N.
        • Habermann E.B.
        • Tepper J.E.
        • Durham S.B.
        • Virnig B.A.
        Risk of pelvic fractures in older women following pelvic irradiation.
        JAMA. 2005; 294: 2587-2593
        • Razavian N.
        • Laucis A.
        • Sun Y.
        • et al.
        Radiation-induced insufficiency fractures after pelvic irradiation for gynecologic malignancies: a systematic review.
        Int J Radiat Oncol Biol Phys. 2020; 108: 620-634
        • Salcedo M.P.
        • Sood A.K.
        • Jhingran A.
        • et al.
        Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: a prospective study of 239 women.
        Cancer. 2020; 126: 2607-2613
        • Sapienza L.G.
        • Salcedo M.P.
        • Ning M.S.
        • et al.
        Pelvic insufficiency fractures after external beam radiation therapy for gynecologic cancers: a meta-analysis and meta-regression of 3929 patients.
        Int J Radiat Oncol Biol Phys. 2020; 106: 475-484
        • Zhong X.
        • Dong T.
        • Tan Y.
        • et al.
        Pelvic insufficiency fracture or bone metastasis after radiotherapy for cervical cancer? The added value of DWI for characterization.
        Eur Radiol. 2020; 30: 1885-1895
        • Eastlake L.
        • Sheridan B.
        • Yiannakis D.
        Insufficiency fractures in postmenopausal gynaecological patients receiving pelvic radiotherapy: can these be prevented by optimisation of bone health?.
        Clin Oncol (R Coll Radiol). 2020; 32: 344-345
        • van den Blink QU
        • Garcez K
        • Henson CC
        • Davidson SE
        • Higham CE
        Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults.
        Cochrane Database Syst Rev. 2018; 4: CD010604
        • Delanian S.
        • Lefaix J.L.
        • Pradat P.F.
        Radiation-induced neuropathy in cancer survivors.
        Radiother Oncol. 2012; 105: 273-282
        • Yi S.K.
        • Mak W.
        • Yang C.C.
        • et al.
        Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of radiation-induced lumbosacral plexopathy.
        Int J Radiat Oncol Biol Phys. 2012; 84: 376-382
        • Pisani C.
        • Deantonio L.
        • Surico D.
        • et al.
        Quality of life in patients treated by adjuvant radiotherapy for endometrial and cervical cancers: correlation with dose-volume parameters.
        Clin Transl Oncol. 2016; 18: 901-908
        • Tunio M.
        • Al Asiri M.
        • Bayoumi Y.
        • et al.
        Lumbosacral plexus delineation, dose distribution, and its correlation with radiation-induced lumbosacral plexopathy in cervical cancer patients.
        Onco Targets Ther. 2015; 8: 21-27
        • Hwang E.
        • Son H.
        • Kim J.
        • Moon S.
        • Lee H.
        MR Imaging of Radiation-Induced Lumbosacral Plexopathy, as a Rare Complication of Concomitant Chemo-Radiation for Cervical Cancer. Investigative Magnetic Resonance Imaging. Investigative.
        Magn Reson Imaging. 2020; 24: 46-50
        • Mbatani N.
        • Olawaiye A.B.
        • Prat J.
        Uterine sarcomas.
        Int J Gynaecol Obstet. 2018; 143: 51-58